Health · 4 views
Novel drug shows promise in an early phase trial in heart failure
Source Story Brief Updated 10h 11m ago
Health 
Story intelligence Beta
Confidence Limited Single-outlet story
Views 4 Community interest
Brief read ~32 words
Story Brief
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Digital strategy helps patients with heart failure to receive proven medicationContinue reading
- After TAVI, anticoagulants outperform antiplatelet agents at preventing clotsContinue reading
- Public confidence in one's own health care provider remains highContinue reading
- High fertility costs push Americans abroad for IVF treatmentContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow